This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
News|Articles|November 15, 2016
- Pharmaceutical Technology-11-15-2016
- Volume 2016 eBook
- Issue 3
Too Much by Half: Misapplication of the Half-Cycle Approach to Sterilization
Author(s)James P. Agalloco
The half-cycle method for validating sterilization can have adverse effects on materials if used for steam sterilization.
Advertisement
The half-cycle method for validating sterilization, although necessary in its original context of ethylene oxide sterilization, can have adverse effects on materials if used for steam sterilization.
The author describes some of these potential results and reviews historical and current thinking on validation of sterilization processes.
Download Pharmaceutical Technology’s
.
Articles in this issue
almost 10 years ago
Extending QMS to Contract Partnersalmost 10 years ago
Investigation Effectiveness Drives Human Performance Excellencealmost 10 years ago
Is Global Regulatory Gridlock Slowing Modernization?almost 10 years ago
Paperless Batch Records for the Massesalmost 10 years ago
Could Greater Transparency Improve Pharmaceutical Quality and Compliance?almost 10 years ago
Ensuring Quality in Pharmaceutical Raw Materialsalmost 10 years ago
Microbiological Testing: Time is of the EssenceAdvertisement
Related to this article
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
Richard Jaenisch explains what FDA's real-world use case database means for CMC and quality teams navigating NAMs.
Boyang Wang, Immortal Dragons, explains how FDA’s Expedited IND Pilot and research partners could speed serial steps to first-in-human trials compared to China’s 818 Decree.
This article examines how modern automation platforms create the digital foundation required for Pharma 4.0 by integrating manufacturing systems, centralized data management, Industrial Internet of Things connectivity, electronic batch production records, and AI-driven analytics.
Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
What the Olanzapine Depot Approval Means for CMC Teams
2
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
3
Q&A: Patient-Centric Drug Development Should Start at Product Definition
4
PharmTech Weekly Roundup—Oct. 8, 2026: CPHI Highlights
5